ArticleCureus2026
Epidemiology and Outcomes of Acute Pulmonary Embolism in Seychelles: A National Cohort Study With a Subgroup Analysis of Systemic Thrombolysis Efficacy and Safety in Intermediate-Risk Pulmonary Embolism.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Pulmonary embolism (PE) is an important cause of cardiovascular morbidity and mortality worldwide. Data from Small Island Developing States (SIDS) in Africa are limited. This study describes the epidemiology of acute PE in Seychelles and examines outcomes associated with different management approaches in patients with intermediate-risk PE. Methods This retrospective observational cohort study was conducted at Seychelles Hospital, Victoria, the national tertiary referral hospital and principal public healthcare facility in the Republic of Seychelles. We conducted a retrospective observational cohort study of all adults with confirmed acute PE managed in Seychelles between January 1, 2019, and December 31, 2025. Temporal trends in incidence, mortality, and hospital length of stay were evaluated. An exploratory subgroup analysis was performed in patients with intermediate-risk PE managed between January 1, 2019, and May 31, 2026, to assess clinical outcomes across this heterogeneous cohort. Patients were grouped according to treatment strategy: systemic thrombolysis followed by anticoagulation (Group A; n = 48) or anticoagulation alone (Group B; n = 12). Clinical, physiological, echocardiographic, and safety outcomes were assessed. Results A total of 389 patients with acute PE were identified during the study period. Females accounted for 231 (59.4%) cases and males for 158 (40.6%). Annual case numbers increased from 36 in 2019 to 84 in 2024 before decreasing to 69 in 2025. Overall crude mortality was 7.5% (29/389), ranging from 20.0% in 2020 to 0.0% in 2025. Among patients with intermediate-risk PE, the observed survival was higher in the thrombolysis group than in the anticoagulation-only group (47/48 (97.9%) vs. 8/12 (66.7%); p = 0.0045). In the thrombolysis group, 32 patients out of the 48 received tenecteplase in myocardial infarction dose as a thrombolytic agent and 16 patients received alteplase. Significant improvements were observed following thrombolysis in oxygen saturation (p < 0.001), PaO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.